A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead resubmits application to FDA for approval of long-acting injectable HIV drug lenacapavir after FDA refused authorization in February due to drug’s compatibility with borosilicate glass vial; Gilead now using aluminosilicate glass vial for drug

Gilead signs WHO’s Kigali Declaration to prevent, control, eliminate neglected tropical diseases; Gilead to continue to donate drugs to treat, eliminate parasitic disease visceral leishmaniasis in tropical, subtropical regions

Gilead names Stacey Ma Executive VP for pharmaceutical development, manufacturing, replacing Taiyin Yang who is retiring; Gilead to focus manufacturing on West Coast of US, with plans to expand manufacturing near current Oceanside, California, facility

FDA lifts clinical hold on Gilead’s injectable lenacapavir HIV treatment, pre-exposure prophylaxis as Gilead changes borosilicate glass vials to aluminosilicate glass vials; hold was from concerns about drug’s compatibility with borosilicate vials

Gilead and Dragonfly Therapeutics announce strategic research collaboration to develop natural killer cell engagers for oncology, inflammation; Gilead makes US$300.0M payment to Dragonfly for rights to investigational immunotherapy program DF7001

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count